Weer iets uit het Exas forum: zeker interessant ivm hun pipeline:
an interesting read from scutify on DDW
by ranjovance
Benchmark Exact Sciences Corporation (EXAS)
Abstracts from Digestive Disease Week 2015 Support Wider Use of
Cologuard and EXAS Pipeline
Six abstracts supporting Cologuard and Exact Science’s, a Buy rated stock with a $31
Price Target, were presented at Digestive Disease Week 2015 over the weekend.
The abstracts support both widening the use of Cologuard, but also pointed to
progress in the company’s pipeline, especially related to esophageal cancer. While
we were not present at the meeting, we do believe that results such as these
demonstrate the adoptability of the Cologuard test and give us some positive
feelings about the company’s pipeline of products.
To summarize the abstracts. Two of the abstracts deal directly with Cologuard, two
of the abstracts are related to the company’s pipeline, one related to being able to
detect DNA markers in tissue and one concerns a cost-effectiveness study in
ulcerative colitis. The first Cologuard related abstract suggests from a single center
study that the sensitivity of Cologuard testing for detection of advanced lesions or
all adenomas in African Americans was similar to or exceeded that of other racial
groups, with comparable specificity. Given the known racial disparities in receipt of
colonoscopy, this noninvasive test may offer a promising screening method for this
population